AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.
Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth
